Arzerra ofatumumab: Interim Phase II data

Interim data from a single-arm, open-label, international Phase II trial in 81 patients who are ineligible for or relapsed following stem cell transplantation showed that ofatumumab produced an ORR of 11%, with a median duration of response of 6.9 months. Genmab said the observed response rate suggests "the need to combine CD20 agents with cytotoxic chemotherapeutic agents in further investigations of CD20 therapy in such heavily pretreated DLBCL patient populations." The most common adverse events included infections, diarrhea, fatigue, peripheral edema and neutropenia. Patients received a single 300 mg IV infusion of ofatumumab followed by 7 once-weekly 1,000 mg IV infusions. ...